AI assistant
Nautilus Biotechnology, Inc. — Director's Dealing 2021
Jun 9, 2021
34183_dirs_2021-06-09_fe2e20c6-c6cb-449b-8029-26744d91b974.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Nautilus Biotechnology, Inc. (NAUT)
CIK: 0001808805
Period of Report: 2021-06-09
Reporting Person: Epperly Melissa B, (Director)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.0 | 2031-01-31 | Common Stock (72561.0) | Direct |
Footnotes
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan (the "Plan")) through each vesting date, one thirty-sixth (1/36th) of the shares subject to the Option shall vest each month over the thirty-six (36) months following the Vesting Commencement Date (as defined below) on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 31, 2021.